GeneDx Holdings Corp.
WGS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.59 | -0.23 | 0.44 | -0.58 |
| FCF Yield | 0.31% | 0.31% | 0.16% | -0.30% |
| EV / EBITDA | -8,863.24 | 152.44 | 10,627.95 | 146.59 |
| Quality | ||||
| ROIC | -0.82% | 2.32% | -1.29% | 2.40% |
| Gross Margin | 72.40% | 69.04% | 67.13% | 69.22% |
| Cash Conversion Ratio | -2.07 | 0.96 | -1.56 | -0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | 24.88% | 15.29% | 13.82% | 9.18% |
| Free Cash Flow Growth | 19.18% | 98.64% | 165.02% | -23.65% |
| Safety | ||||
| Net Debt / EBITDA | -48.84 | 2.29 | 64.12 | 2.16 |
| Interest Coverage | -5.78 | 10.97 | -7.11 | 12.62 |
| Efficiency | ||||
| Inventory Turnover | 3.05 | 2.66 | 2.26 | 2.76 |
| Cash Conversion Cycle | 69.16 | 65.90 | 37.55 | 43.65 |